Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy)

Breast Journal

Volumn 19, Issue 1, 2013, Pages 10-21

  Razzaboni, Elisabetta ^a   Toss, Angela ^a   Cortesi, Laura ^a   Marchi, Isabella ^a   Sebastiani, Federica ^a   De Matteis, Elisabetta ^a   Federico, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

acceptability; breast cancer risk; chemoprevention; compliance

Indexed keywords

ANASTROZOLE; PLACEBO;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DERMATITIS; DOUBLE BLIND PROCEDURE; EYE DISCHARGE; FAMILY; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; GENERAL PRACTITIONER; HEADACHE; HEALTH BELIEF; HEALTH STATUS; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; LARYNX EDEMA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MUSCLE DISEASE; NIGHT SWEAT; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT DECISION MAKING; POSTMENOPAUSE; PROSPECTIVE PRICING; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; SOCIAL STATUS; VAGINA; VAGINA BLEEDING; VASCULAR DISEASE; WEAKNESS; WEIGHT GAIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTICARCINOGENIC AGENTS; ARTHRALGIA; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DECISION MAKING; DOUBLE-BLIND METHOD; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; HOT FLASHES; HUMANS; ITALY; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; PATIENT DROPOUTS; TREATMENT REFUSAL; TRIAZOLES; VAGINAL DISEASES;

EID: 84872277433     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12045     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Brown PH, Lippman SM,. Chemoprevention of breast cancer. Breast Cancer Res Treat 2000; 62: 1-17.
3. Fisher B, Constantino JP, Wickerham DL, et al,. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
4. Vogel VG, Costantino JP, Wickerham DL, et al,. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2727-41.
5. Vogel VG, Costantino JP, Wickerham DL, et al,. Update of the NSABP Study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010; 3: 696-706.
6. Powles T, Eeles R, Ashley S, et al,. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998; 352: 98-101.
7. Veronesi U, Maisonneuve P, Costa A, et al,. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-7.
8. Cuzick J, Forbes J, Edwards R, et al,. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24.
9. Cummings SR, Eckert S, Krueger KA, et al,. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999; 281: 2189-97.
10. Cuzick J, Powles T, Veronesi U, et al,. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
11. Visvanathan K, Chlebowski RT, Hurley P, et al,. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27: 3235-58.
12. Goss PE, Ingle JN, Alés-Martínez JE, et al,. NCIC CTG MAP.3 Study investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-91.
13. Evans D, Lalloo F, Shenton A, Boggis C, Howell A,. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 2001; 358: 889-90.
14. Rondanina G, Puntoni M, Severi G, et al,. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol 2008; 26: 1537-43.
15. Julian-Reynier CM, Bouchard LJ, Evans DG, et al,. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001; 92: 959-68.
16. Port ER, Montgomery LL, Heerdt AS, Borgen PI,. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8: 580-5.
17. Lovegrove E, Rumsey N, Harcourt D, Cawthorn SJ,. Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer. Psycho-Oncology 2000; 9: 193-202.
18. Pritchard KI,. Is tamoxifen effective in prevention of breast cancer? Lancet 1998; 352: 80-1.
19. Cuzick J,. Chemoprevention of breast cancer. Breast Cancer 2008; 15: 10-16.
20. Cuzick J,. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008; 8: 1377-85.
21. Cortesi L, Turchetti D, Marchi I, et al,. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer 2006; 6: 210.
22. Cyrus-Davis MS, Strom SS,. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psycho-oncology 2001; 10: 521-33.
23. Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N,. Women's views on chemoprevention of breast cancer. Qualitative study. Can Fam Physician 2006; 52: 624-5.
24. Fallowfield L, Fleissig A, Edwards R, et al,. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participanting in two randomized controlled trials. J Clin Oncol 2001; 19: 1885-92.
25. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM,. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004; 22: 4951-7.
26. Maurice A, Howell A, Evans DG, O'Neil AC, Scobie S,. Predicting Compliance in a Breast Cancer Prevention Trial. Breast J 2006; 12: 446-50.
27. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B,. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17: 2659-69.
28. Land SR, Wickerham DL, Costantino JP, et al,. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention the NSABP Study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2742-51.
29. Cuzick J,. Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer Prev Res (Phila) 2010; 3: 689-91.